Oculis Holding AG Ordinary shares (OCS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $425.67M
Last updated: Nov 17, 2026 at 11:05 AM ET
Oculis Holding AG Ordinary shares (OCS) Competitors
The companies most similar to Oculis Holding AG Ordinary shares are Ocugen (OCGN), Ovid Therapeutics (OVID) and Opus Genetics (IRD). By market cap, Oculis Holding AG Ordinary shares ranks 9th of the 13 companies on this page; Ocular Therapeutix (OCUL) is the largest at $1.37B.
Peer Comparison
OCS's revenue growth of -97.1% is below the peer median of -5.8%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Oculis Holding AG Ordinary shares (OCS) | $425.67M | N/A | N/A | 0.0% | N/A | -97.1% | 0.00% |
| Ocugen Inc (OCGN) | $280.88M | N/A | 54.9x | 0.0% | 271.0% | 11.4% | 0.00% |
| Ovid Therapeutics Inc (OVID) | $479.38M | N/A | 335.8x | 0.0% | N/A | -88.3% | 0.00% |
| Opus Genetics, Inc. (IRD) | $384.68M | N/A | 52.0x | 0.0% | -145.1% | -63.1% | 0.00% |
| Ocular Therapeutix Inc (OCUL) | $1.37B | N/A | 26.9x | 0.0% | -52.1% | -11.5% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Avalo Therapeutics Inc (AVTX) | $448.71M | N/A | N/A | 0.0% | N/A | -69.3% | 0.00% |
| Orchestra BioMed Holdings Inc. (OBIO) | $570.61M | N/A | 14.7x | -182.5% | -97.0% | -89.4% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $683.26M | N/A | 8.1x | -124.8% | -7.3% | 178.1% | 0.00% |
| Tectonic Therapeutic, Inc. (TECX) | $413.27M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $464.04M | N/A | 29.0x | 0.0% | -32.8% | -5.8% | 0.00% |
Similar Companies
These are the 12 companies most similar to Oculis Holding AG Ordinary shares, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ocugen Inc (OCGN) | Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. | OCGN competitors |
| Ovid Therapeutics Inc (OVID) | Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medications for patients and families with neurological disorders in the United States. | OVID competitors |
| Opus Genetics, Inc. (IRD) | Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. | IRD competitors |
| Ocular Therapeutix Inc (OCUL) | Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development... | OCUL competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| Avalo Therapeutics Inc (AVTX) | Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved... | AVTX competitors |
| Orchestra BioMed Holdings Inc. (OBIO) | Orchestra BioMed Holdings, Inc. is a therapeutic device company that develops therapeutic treatments and products for cardiovascular diseases. | OBIO competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. | |
| Tectonic Therapeutic, Inc. (TECX) | Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel... | TECX competitors |
Frequently Asked Questions About OCS
Who are Oculis Holding AG Ordinary shares' main competitors?
The companies most similar to Oculis Holding AG Ordinary shares include Ocugen (OCGN), Ovid Therapeutics (OVID), Opus Genetics (IRD), Ocular Therapeutix (OCUL) and Olema Pharmaceuticals (OLMA), listed from the closest match.
Who is Oculis Holding AG Ordinary shares' biggest competitor?
Ocular Therapeutix (OCUL) is the largest of the similar companies at $1.37B; Ocugen (OCGN) is the closest match by business profile, size, sector and industry.
How does OCS stock compare with its competitors?
OCS' net margin is 0.0% against a peer median of 0.0%.
Which of Oculis Holding AG Ordinary shares' competitors pays a higher dividend?
Oculis Holding AG Ordinary shares pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Oculis Holding AG Ordinary shares bigger than its competitors?
No. Oculis Holding AG Ordinary shares is 9th by market cap among the 13 companies on this page; the largest is Ocular Therapeutix (OCUL) at $1.37B.
OCS pages: Overview, Financials, Competitors